Biorestorative Therapies, Inc. (BRTX) Announces Fourth Quarter Loss, Falls Short of Revenue Projections

Biorestorative Therapies, Inc. (BRTX) Q4 Earnings Overview

Biorestorative Therapies, Inc. (BRTX) reported a quarterly net loss of $0.32 per share, which was narrower than the consensus forecast of a $0.37 loss. In comparison, the company posted a loss of $0.20 per share in the same period last year. These results exclude one-time items.

This quarter’s performance resulted in a positive earnings surprise of 13.51%. In the previous quarter, the company’s actual loss of $0.38 per share matched expectations, resulting in no surprise. Over the past year, BRTX has exceeded analyst earnings per share (EPS) estimates in two out of four quarters.

For the quarter ending December 2025, Biorestorative Therapies generated $20,000 in revenue, falling short of the consensus estimate by 90.2%. This compares to $40,000 in revenue reported a year earlier. The company has only surpassed revenue expectations once in the last four quarters.

The direction of BRTX’s stock price in the near term will likely be influenced by management’s comments during the earnings call, as well as future earnings projections.

Since the start of the year, shares of Biorestorative Therapies have declined approximately 73.6%, whereas the S&P 500 has dropped by 3.7% over the same period.

What Lies Ahead for Biorestorative Therapies?

Despite underperforming the broader market this year, investors are now wondering about the future prospects for Biorestorative Therapies’ stock.

While there is no definitive answer, one useful indicator is the company’s earnings outlook, which includes both current consensus estimates for upcoming quarters and any recent changes to those estimates.

Studies have shown that short-term stock price movements are closely linked to trends in earnings estimate revisions. Investors can monitor these changes themselves or use established tools like the Zacks Rank, which has a strong track record of leveraging estimate revisions.

Prior to this earnings announcement, analyst estimate revisions for Biorestorative Therapies were mixed. The latest results may influence future revisions, but as of now, the stock holds a Zacks Rank #3 (Hold), suggesting it is expected to perform in line with the market.

It will be important to watch how analyst estimates for the next few quarters and the current fiscal year evolve. At present, the consensus forecast calls for a loss of $0.49 per share on $250,000 in revenue for the next quarter, and a loss of $1.17 per share on $1.3 million in revenue for the full fiscal year.

Investors should also consider the broader industry outlook, as it can significantly impact individual stock performance. The Medical - Biomedical and Genetics sector currently ranks in the bottom 40% among over 250 Zacks industries. Historically, the top half of Zacks-ranked industries outperforms the lower half by more than two to one.

Industry Comparison: RenovoRx, Inc. (RNXT)

Another company in the same sector, RenovoRx, Inc. (RNXT), has not yet released its results for the quarter ending December 2025, with the report expected on March 30.

RenovoRx is projected to report a quarterly loss of $0.08 per share, reflecting a 33.3% improvement from the prior year. The consensus EPS estimate for this period has remained steady over the past month.

Revenue for RenovoRx is anticipated to reach $500,000, representing a significant 1150% increase compared to the same quarter last year.

Is Biorestorative Therapies, Inc. (BRTX) a Good Investment?

If you’re considering investing in Biorestorative Therapies, Inc. (BRTX), you may want to explore top stock picks for the next month. Zacks Investment Research offers a complimentary report on the 7 best stocks to buy now.

Since 1978, Zacks Investment Research has provided independent analysis and tools for investors. Over the past 25 years, the Zacks Rank stock-rating system has delivered an average annual return of 24.08%, more than doubling the S&P 500’s performance between January 1, 1988, and May 6, 2024.

For the latest stock recommendations from Zacks Investment Research, you can download the 7 Best Stocks for the Next 30 Days.